A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Seagen Inc.
Peking University
Sun Yat-sen University
AIO-Studien-gGmbH
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
West China Hospital
Harbin Medical University
CSPC Ouyi Pharmaceutical Co., Ltd.
Khon Kaen University
Benaroya Research Institute
National Cancer Institute (NCI)
Galectin Therapeutics Inc.
Peking University
Stanford University
University of Utah